These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30311789)

  • 1. Thoughts on Chemistry, Manufacturing, and Control of Cell Therapy Products for Clinical Application.
    Wei W; Luo J
    Hum Gene Ther; 2019 Feb; 30(2):119-126. PubMed ID: 30311789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
    Lim JO
    Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion processes for cell-based therapies.
    Scibona E; Morbidelli M
    Biotechnol Adv; 2019 Dec; 37(8):107455. PubMed ID: 31629791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell therapy manufacturing: process development technologies and facility design options.
    Abbasalizadeh S; Pakzad M; Cabral JMS; Baharvand H
    Expert Opin Biol Ther; 2017 Oct; 17(10):1201-1219. PubMed ID: 28699788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of Good Manufacturing Practice (GMP) for Biomedical Cell Products.
    Tulina MA; Pyatigorskaya NV
    Bull Exp Biol Med; 2018 Mar; 164(4):579-582. PubMed ID: 29504094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical grade cell manipulation.
    Giordano R; Lazzari L; Rebulla P
    Vox Sang; 2004 Aug; 87(2):65-72. PubMed ID: 15355496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
    Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
    J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Regulatory Pathway for Advanced Cell Therapy and Gene Therapy Products in Brazil: A Road to Be Built.
    de Freitas DR
    Adv Exp Med Biol; 2015; 871():213-9. PubMed ID: 26374221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
    Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
    Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
    Harrison RP; Rafiq QA; Medcalf N
    Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development.
    Carmen J; Burger SR; McCaman M; Rowley JA
    Regen Med; 2012 Jan; 7(1):85-100. PubMed ID: 22168500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-clinical assessment of cell therapy products: the perspective from five Asian countries/regions based on regulatory guidelines and the underpinning rationales.
    Yoneda T; Choi BH; Gupta PK; Ho CY; Tsui YP; Wang LM; Fujiwara Y; Karasawa H; Moriya Y; Bando K; Kamiyama Y; Kanki M; Omura K; Watanabe T; Bae Y; Chou FC; Ham DS; Lee JY; Liu G; Liu Y; Ooi J; Tsurumaki Y
    Cytotherapy; 2021 Oct; 23(10):874-885. PubMed ID: 34116946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncertainty and innovation: Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments.
    Isasi R; Rahimzadeh V; Charlebois K
    Appl Transl Genom; 2016 Dec; 11():27-39. PubMed ID: 28018847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-based therapy technology classifications and translational challenges.
    Mount NM; Ward SJ; Kefalas P; Hyllner J
    Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1680):20150017. PubMed ID: 26416686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Oversight of Cell, Tissue, and Gene Therapy Products in Singapore.
    Ong LL
    Adv Exp Med Biol; 2023; 1430():197-210. PubMed ID: 37526849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Therapy Regulation in Taiwan.
    Chen YC; Cheng HF; Yeh MK
    Cell Transplant; 2017 Mar; 26(3):483-492. PubMed ID: 27697103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.